Figure 4.

Increased Mybl2 expression supports stem-related gene signatures in murine and human prostate cancer. A, Two-dimensional principal component analysis visualization of bulk RNA-seq analysis performed in DKO Ctl vs. DKO Mybl2 KO cells (left) and PPKO Ctl vs. PPKO Mybl2 KO cells. B, Venn diagram representation of down- and upregulated genes from the DEG analysis between DKO Mybl2 KO vs. DKO Ctl cells and PPKO Mybl2 KO vs. PPKO Ctl cells showed that both cell lines shared 197 down and 127 upregulated genes. The P adjusted value used to calculate the DEG was <0.05 and the LFC was < or > 2. C, Bar chart visualization of the top 10 enriched terms and their P values using ENCODE and ChIP-x enrichment analysis (ChEA), ChEA 2022, and Hallmarks 2020 databases using the 197 downregulated genes shared between DKO Mybl2 KO and PPKO Mybl2 KO cells. All pathways listed were statistically significant with P < 0.05. D, Normalized gene expression values for TCGA-PRAD and (E) SU2C samples from patient with CRPC show high MYBL2 expression (top 25% of samples) is associated with significantly increased expression of gene signatures for NEPC (NE), ASC, and ESC signatures when compared with patient samples with lowest MYBL2 expression (bottom 25% of samples).